French Institute of Health and Medical Research-ko ikertzaileekin lankidetzan egindako argitalpenak (34)

2024

  1. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

    Journal of Extracellular Vesicles, Vol. 13, Núm. 2

2021

  1. Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings

    Molecular Psychiatry, Vol. 26, Núm. 8, pp. 4529-4543

2020

  1. Premorbid Adjustment and IQ in Patients with First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship with Cannabis Use

    Schizophrenia Bulletin, Vol. 46, Núm. 3, pp. 517-529

2019

  1. HIV-1 molecular transmission clusters in nine European countries and Canada: Association with demographic and clinical factors

    BMC Medicine, Vol. 17, Núm. 1

2016

  1. Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: Raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART

    Journal of Antimicrobial Chemotherapy, Vol. 71, Núm. 4, pp. 1056-1062

  2. Infection-related and -unrelated malignancies, HIV and the aging population

    HIV Medicine, Vol. 17, Núm. 8, pp. 590-600

2015

  1. A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances

    Pharmacogenomics Journal, Vol. 15, Núm. 2, pp. 172-176

  2. Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study

    HIV Medicine, Vol. 16, Núm. 9, pp. 533-543

  3. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

    PLoS Medicine, Vol. 12, Núm. 3

  4. Further evidence of DEPDC7 DNA hypomethylation in depression: A study in adult twins

    European Psychiatry, Vol. 30, Núm. 6, pp. 715-718

2014

  1. A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe

    Infection, Vol. 42, Núm. 4, pp. 757-762

  2. Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: The D:A:D study

    BMC Nephrology, Vol. 15, Núm. 1

  3. Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe

    PLoS ONE, Vol. 9, Núm. 1

  4. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

    AIDS, Vol. 28, Núm. 16, pp. 2461-2473

2013

  1. Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients

    PLoS ONE, Vol. 8, Núm. 5

  2. Predicting suicidal behavior: Are we really that far along? Comment on "discovery and validation of blood biomarkers for suicidality"

    Current Psychiatry Reports, Vol. 15, Núm. 12

2012

  1. Hepatitis c virus viremia increases the Incidence of chronic kidney disease in HIV-infected Patients

    AIDS, Vol. 26, Núm. 15, pp. 1917-1926

  2. Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: The EuroSIDA study

    PLoS ONE, Vol. 7, Núm. 7

2011

  1. A376s in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy

    Journal of Infectious Diseases, Vol. 204, Núm. 5, pp. 741-752

  2. An international collaboration to standardize HIV-2 viral load assays: Results from the 2009 ACHI EV 2E quality control study

    Journal of Clinical Microbiology, Vol. 49, Núm. 10, pp. 3491-3497